Exchange: NASDAQ·Updated 05:45 PM EDT
News
all
press releases
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of -10.24% and -2.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?
Zacks
Best Momentum Stocks to Buy for July 13th
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
Zacks
New Strong Buy Stocks for July 13th
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
Zacks
New Strong Buy Stocks for July 9th
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Zacks
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Zacks
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
Zacks

Advertisement|Remove ads.